Melody Noel Brown

Array ( [id] => 18065711 [patent_doc_number] => 20220396798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => NOVEL MRNA COMPOSITION AND PRODUCTION METHOD FOR USE IN ANTI-VIRAL AND ANTI-CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 17/489357 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17489357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17793501 [patent_doc_number] => 20220252593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Methods of Treating Transthyretin (TTR) Mediated Amyloidosis [patent_app_type] => utility [patent_app_number] => 17/475098 [patent_app_country] => US [patent_app_date] => 2021-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17475098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058417 [patent_doc_number] => 11937604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => PIGM gene related to nilaparvata lugens (StAl) reproduction and application thereof [patent_app_type] => utility [patent_app_number] => 17/474028 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 3017 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17474028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17905720 [patent_doc_number] => 11459566 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-10-04 [patent_title] => Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/472227 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 72007 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556278 [patent_doc_number] => 11312961 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-04-26 [patent_title] => Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/472255 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 101189 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482578 [patent_doc_number] => 20220090082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => GAPMER ANTISENSE OLIGONUCLEOTIDES TARGETING SARS-COV-2 FOR TREATING COVID 19 [patent_app_type] => utility [patent_app_number] => 17/471719 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692981 [patent_doc_number] => 20230323349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => TARGETING ENHANCER RNAS FOR THE TREATMENT OF PRIMARY BRAIN TUMORS [patent_app_type] => utility [patent_app_number] => 18/043511 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299915 [patent_doc_number] => 20210395754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/464474 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8039 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784889 [patent_doc_number] => 11408002 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-08-09 [patent_title] => Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/400317 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 72339 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556277 [patent_doc_number] => 11312960 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-04-26 [patent_title] => Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/400259 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 101129 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200446 [patent_doc_number] => 20210340541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS AND COMPOSITIONS TO INHIBIT METASTASIS AND TO TREAT FIBROSIS AND TO ENHANCE WOUND HEALING [patent_app_type] => utility [patent_app_number] => 17/377351 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460614 [patent_doc_number] => 20220073919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => THERAPEUTIC OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 17/377046 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 145457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17357106 [patent_doc_number] => 20220017902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER [patent_app_type] => utility [patent_app_number] => 17/375785 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198741 [patent_doc_number] => 20210338835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS FOR TREATING SUBJECTS SUFFERING FROM ACUTE MYELOID LEUKEMIA WITH FLT3 LIGAND-TARGETED MIR-150 NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/375548 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200075 [patent_doc_number] => 20210340170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => 5'-CAP COMPOUNDS AND THEIR USES IN STABILIZING RNA, EXPRESSING PROTEINS AND IN THERAPY [patent_app_type] => utility [patent_app_number] => 17/371935 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720752 [patent_doc_number] => 20220213472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS [patent_app_type] => utility [patent_app_number] => 17/372173 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17372173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18492401 [patent_doc_number] => 11697812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA [patent_app_type] => utility [patent_app_number] => 17/305177 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 75128 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548476 [patent_doc_number] => 20220119817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => Polycomb-associated Non-Coding RNAs [patent_app_type] => utility [patent_app_number] => 17/350018 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563459 [patent_doc_number] => 20220127608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION [patent_app_type] => utility [patent_app_number] => 17/339366 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18147574 [patent_doc_number] => 20230021431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => OLIGONUCLEOTIDES FOR SARS-CoV-2 MODULATION [patent_app_type] => utility [patent_app_number] => 17/333839 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333839 [rel_patent_id] =>[rel_patent_doc_number] =>)